Pherecydes Pharma Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 27

Employees

  • Latest Deal Type
  • M&A

Pherecydes Pharma General Information

Description

Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on various bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pherecydes Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 23-Jun-2023 000.00 Completed Generating Revenue
9. PIPE 22-Sep-2022 00.00 000.00 000.00 Completed Generating Revenue
8. IPO 05-Feb-2021 00.00 000.00 000.00 Completed Generating Revenue
7. Later Stage VC 30-Oct-2019 00.00 000.00 000.00 Completed Generating Revenue
6. Grant 01-Feb-2018 00.000 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 16-Jan-2018 000.00 000.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series A) 18-Mar-2015 00.000 00.000 Completed Generating Revenue
3. Grant 18-Jan-2012 00.000 00.000 Completed Generating Revenue
2. Angel (individual) 01-Jan-2007 $3.03M $3.03M Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Pherecydes Pharma’s complete valuation and funding history, request access »

Pherecydes Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
P1 shares 000,000 00.000000 00.00 00.00 00 00.00 0.000
ABSA 1 000,000 00.000000 00.00 00.00 00 00.00 00.00
P1 shares 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 23,413 $1.104264 $5.99 $5.99 1x $5.99 0.67%
P1 shares 1,190,232 $1.104264 $5.99 $5.99 1x $5.99 34.01%
To view Pherecydes Pharma’s complete cap table history, request access »

Pherecydes Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on va
Drug Discovery
27 As of 2022
000.00
000000&0 000.00

00000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000000000000
Ness Ziona, Israel
00 As of 0000
000.00
000000000 000.00

00000

erit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur s
0000000000000
Paris, France
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pherecydes Pharma Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BiomX Formerly VC-backed Ness Ziona, Israel 00 000.00 000000000 000.00
Eligo Bioscience Venture Capital-Backed Paris, France 00 000.00 00000000000 000.00
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 000 00000 0000000000 0 00000
SynDevRx Venture Capital-Backed Cambridge, MA 000.00 0000000000 0 000.00
Armata Pharmaceuticals Formerly VC-backed Marina del Rey, CA 00 00000 000000000 00000
You’re viewing 5 of 20 competitors. Get the full list »

Pherecydes Pharma Executive Team (7)

Name Title Board Seat Contact Info
Cindy Fevre Ph.D Chief Scientific Officer
Pascal Birman Chief Medical Officer
You’re viewing 2 of 7 executive team members. Get the full list »

Pherecydes Pharma Board Members (10)

Name Representing Role Since
Didier Hoch Self Chairman 000 0000
Eric Leire MD Self Supervisory Board Member 000 0000
Guy Rigaud Self Supervisory Board Member 000 0000
Leila Nicholas GO Capital (France) Supervisory Board Member 000 0000
Maryvonne Hiance Self Vice Chairwoman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Pherecydes Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pherecydes Pharma Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ACE Biotech Incubator Accelerator/Incubator 000 0000 000000 0
Auriga Partners (Paris) Venture Capital Minority 000 0000 000000 0
DGA France Government 000 0000 000000 0
Elaia Partners Venture Capital Minority 000 0000 000000 0
FaDiese Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Pherecydes Pharma FAQs

  • When was Pherecydes Pharma founded?

    Pherecydes Pharma was founded in 2006.

  • Who is the founder of Pherecydes Pharma?

    Jérôme Gabard Ph.D and Manuel Gea are the founders of Pherecydes Pharma.

  • What is the size of Pherecydes Pharma?

    Pherecydes Pharma has 27 total employees.

  • What industry is Pherecydes Pharma in?

    Pherecydes Pharma’s primary industry is Drug Discovery.

  • Is Pherecydes Pharma a private or public company?

    Pherecydes Pharma is a Private company.

  • What is Pherecydes Pharma’s current revenue?

    The current revenue for Pherecydes Pharma is 000000.

  • How much funding has Pherecydes Pharma raised over time?

    Pherecydes Pharma has raised $34.3M.

  • Who are Pherecydes Pharma’s investors?

    ACE Biotech Incubator, Auriga Partners (Paris), DGA France, Elaia Partners, and FaDiese are 5 of 12 investors who have invested in Pherecydes Pharma.

  • Who are Pherecydes Pharma’s competitors?

    BiomX, Eligo Bioscience, Vedanta Biosciences, SynDevRx, and Armata Pharmaceuticals are some of the 20 competitors of Pherecydes Pharma.

  • When was Pherecydes Pharma acquired?

    Pherecydes Pharma was acquired on 23-Jun-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »